Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.
Fathi AT, Blonquist TM, Hernandez D, Amrein PC, Ballen KK, McMasters M, Avigan DE, Joyce R, Logan EK, Hobbs G, Brunner AM, Joseph C, Perry AM, Burke M, Behnan T, Foster J, Bergeron MK, Moran JA, Ramos AY, Som TT, Rae J, Fishman KM, McGregor KL, Connolly C, Neuberg DS, Levis MJ.
Fathi AT, et al. Among authors: hernandez d.
Cancer. 2018 Jan 15;124(2):306-314. doi: 10.1002/cncr.31038. Epub 2017 Sep 28.
Cancer. 2018.
PMID: 28960265
Free PMC article.